Fig. 6. CD73 neutralization in combination with A_2A and A_2B antagonists leads to significant EG7 tumor regression.

a Schematic illustration of timeline and treatments of EG7-bearing WT mice with daily i.p. injection of 1 mg kg⁻¹ body weight of A_2A antagonist ZM241385 or A_2B antagonist PSB1115 with or without anti-CD73 treatment. b Tumor progression was examined every day. c The percentage of TIL-CD8 T cells in the EG7 TME and IFN-g-producing CTLs were determined via FACS and summarized. d The percentage of CD73^hi/+ CAFs in the TME following different treatments were analyzed via FACS. e EG7-bearing mice were treated with daily i.p. injection of combined ZM and PSB with or without anti-CD73. Tumor progression was monitored every day. f The percentage of TIL-CD8 T cells and IFN-g-producing CTLs in the EG7 TME were analyzed via FACS. g The percentage of CD73^hi/+ CAFs in the TME of various treated groups were analyzed via FACS. b, e p values were determined via multiple t-tests where the tumor sizes at each time point were compared. c, d, f, g Error bars depict mean ± SEM. p values were determined via two-tailed unpaired Student’s t-test. All experiments were repeated at least two times. Source data are provided in the Source Data file.